LEADER 04413oam 2201021zu 450 001 9910841317503321 005 20230124181430.0 010 $a1-280-55549-1 010 $a9786610555499 010 $a0-470-85183-X 010 $a0-470-84664-X 035 $a(CKB)111087027143202 035 $a(SSID)ssj0000158768 035 $a(PQKBManifestationID)11151728 035 $a(PQKBTitleCode)TC0000158768 035 $a(PQKBWorkID)10149845 035 $a(PQKB)11434406 035 $a(MiAaPQ)EBC4956303 035 $a(Au-PeEL)EBL4956303 035 $a(CaONFJC)MIL55549 035 $a(OCoLC)1024277808 035 $a(EXLCZ)99111087027143202 100 $a20160829d2000 uy 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aFrom genome to therapy : integrating new technologies with drug development 205 $a1st ed. 210 31$a[Place of publication not identified]$cJohn Wiley$d2000 215 $a1 online resource (173 pages) 225 0 $aNovartis Foundation symposium From genome to therapy 300 $aBibliographic Level Mode of Issuance: Monograph 311 $a0-471-62744-5 330 $aThis important and exciting work brings together a high-calibre group of experts to discuss the practical application of genomic information to the development of drugs. Recent technological advances have led to a rapid acceleration in our ability to gather genetic data. The complete genetic sequences are now known for several organisms and accelerated programmes are in place for sequencing many other genomes, including human. The speed with which complete sequencing can be accomplished will continue to increase as new technologies come online. In principle, the scope for developing new diagnostic techniques and drugs is now greater than at any time in human history, but the pathway from genetic information to usable drug is a long and complex one.This major book covers such subjects as the current state of the art in squencing technology, the applications of these new technologies to sequencing the genomes of various organisms, and the challenge of proteomics. Additional contributions deal with legal and ethical implications of the new uses of genetic data, and functional genomics from the point of view of the pharmaceutical industry. 410 0$aNovartis Foundation Symposia 606 $aPharmacogenomics$vCongresses 606 $aPharmacogenetics$vCongresses 606 $aPharmacology 606 $aComputational Biology 606 $aDrug Discovery 606 $aGenetics 606 $aInvestigative Techniques 606 $aBiology 606 $aBiological Science Disciplines 606 $aHealth Occupations 606 $aChemistry, Pharmaceutical 606 $aNatural Science Disciplines 606 $aDisciplines and Occupations 606 $aChemistry 606 $aAnalytical, Diagnostic and Therapeutic Techniques and Equipment 606 $aPharmacogenetics 606 $aDrug Design 606 $aGenomics 606 $aHealth & Biological Sciences$2HILCC 606 $aPharmacy, Therapeutics, & Pharmacology$2HILCC 615 0$aPharmacogenomics 615 0$aPharmacogenetics 615 2$aPharmacology 615 2$aComputational Biology 615 2$aDrug Discovery 615 2$aGenetics 615 2$aInvestigative Techniques 615 2$aBiology 615 2$aBiological Science Disciplines 615 2$aHealth Occupations 615 2$aChemistry, Pharmaceutical 615 2$aNatural Science Disciplines 615 2$aDisciplines and Occupations 615 2$aChemistry 615 2$aAnalytical, Diagnostic and Therapeutic Techniques and Equipment 615 2$aPharmacogenetics 615 2$aDrug Design 615 2$aGenomics 615 7$aHealth & Biological Sciences 615 7$aPharmacy, Therapeutics, & Pharmacology 676 $a615/.19 702 $aBock$b Gregory 702 $aCohen$b Dalia 702 $aGoode$b Jamie 712 02$aNovartis Foundation 712 12$aSymposium on From Genome to Therapy: Integrating New Technologies with Drug Development$f(1999 :$eBasel, Switzerland) 801 0$bPQKB 906 $aBOOK 912 $a9910841317503321 996 $aFrom genome to therapy : integrating new technologies with drug development$94143468 997 $aUNINA